Tempus AI, Inc. (TEM)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Strategic Partnerships Power Tempus AI's Healthcare Expansion
TEM deepens collaborations in oncology and neuroscience using its Lens and Next platforms to accelerate precision medicine.
Tempus AI: TEM Stock To $130?
Tempus AI (NASDAQ: TEM) has already posted a strong 2x gain since its IPO, rising from $37 to $74. Although it trades at a lofty 14x trailing revenue multiple, the company's solid growth trajectory and expanding market opportunity indicate room for continued upside, as outlined below.
Tempus AI's Strong Q2 Fuels Growth Story—More Upside Ahead?
Over the past two years, one of the most interesting healthcare companies to go public is none other than Tempus AI NASDAQ: TEM. In a world where healthcare IPOs are typically dominated by biotech companies that generate little to no revenue, Tempus stands out.
Tempus AI Stock Jumps Post Q2 as EBITDA Breakeven Nears: Buy or Hold?
Tempus AI's soaring Q2 revenues, margin gains and near-EBITDA breakeven position it as a fast-rising force in precision medicine.
TEM Once Again Raises Its 2025 Sales Guidance: What's Driving the Move?
Tempus AI raises 2025 revenue outlook again after strong Q2 growth in genomics and AI-driven oncology solutions.
Tempus AI Stock: Is It A Buy Following Guidance Raise?
Tempus AI delivered strong revenue growth and beat expectations on both revenue and profit, but remains unprofitable at this stage. Sequential improvements in both revenue and loss per share highlight progress, with annualized revenue growth tracking at an impressive rate. Despite the double beat, TEM stock price showed little movement, likely due to high investor expectations and prior consensus outperformance.
Tempus AI: Buy or Sell TEM Stock At $65?
Tempus AI stock has increased by 10% over the past week, fueled by impressive quarterly results and a raised sales forecast for the entire year. The company is now predicting an 82% year-over-year increase in sales, amounting to approximately $126 million.
Tempus AI, Inc. (TEM) Q2 2025 Earnings Call Transcript
Tempus AI, Inc. (NASDAQ:TEM ) Q2 2025 Earnings Conference Call August 8, 2025 8:00 PM ET Company Participants Elizabeth Krutoholow - Vice President of Investor Relations & Competitive Intelligence Eric P. Lefkofsky - Co-Founder, CEO, President & Chairman James Rogers - Chief Financial Officer Conference Call Participants Andrew Frederick Brackmann - William Blair & Company L.L.C.
Compared to Estimates, Tempus (TEM) Q2 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Tempus (TEM) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
TEM's Q2 Earnings & Revenues Beat Estimates, Stock Up in Pre-Market
Tempus AI posts a narrower Q2 loss and an 89.6% revenue surge, driven by genomics growth and new oncology-focused product launches.
Tempus AI (TEM) Reports Q2 Loss, Beats Revenue Estimates
Tempus AI (TEM) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to a loss of $0.63 per share a year ago.
Tempus AI Targets Breast Cancer With Expanded Next - AI Platform
TEM expands its AI-driven Tempus Next platform into breast cancer, targeting key testing gaps to improve care delivery.
